The role of neratinib in HER2-driven breast cancer

Mathew A. Cherian, Cynthia X. Ma

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Up to 25% of patients with early-stage HER2+ breast cancer relapse despite adjuvant trastuzumab-based regimens and virtually all patients with metastatic disease eventually die from resistance to existing treatment options. In addition, recent studies indicate that activating HER2 mutations without gene amplification could drive tumor growth in a subset of HER2-negative breast cancer that is not currently eligible for HER2-targeted agents. Neratinib is an irreversible HER kinase inhibitor with activity as extended adjuvant therapy following standard trastuzumab-based adjuvant treatment in a Phase III trial. Phase II trials of neratinib demonstrate promising activity in combination with cytotoxic agents in trastuzumab resistant metastatic HER2+ breast cancer, and either as monotherapy or in combination with fulvestrant for HER2-mutated breast cancers. We anticipate a potential role for neratinib in the therapy of these patient populations.

Original languageEnglish
Pages (from-to)1931-1943
Number of pages13
JournalFuture Oncology
Issue number22
StatePublished - Sep 2017


  • HER2
  • adjuvant therapy
  • breast cancer
  • neratinib
  • tyrosine kinase inhibitor


Dive into the research topics of 'The role of neratinib in HER2-driven breast cancer'. Together they form a unique fingerprint.

Cite this